Donna L White1, Vlad Ratziu, Hashem B El-Serag. 1. Section of Gastroenterology and Hepatology, Baylor College of Medicine, Michael E. DeBakey VA Medical Center, Houston, TX 77030, USA.
Abstract
BACKGROUND/AIMS: Several studies found hepatitis C (HCV) increases risk of Type II diabetes mellitus (DM). However, others found no or only sub-group specific excess risk. We performed meta-analyses to examine whether HCV infection does increase DM risk in comparison to the general population and in other sub-groups with increased liver disease rates including with hepatitis B (HBV). METHODS: We followed standard guidelines for performance of meta-analyses. Two independent investigators identified eligible studies through structured keyword searches in relevant databases including PubMed. RESULTS: We identified 34 eligible studies. Pooled estimators indicated significant DM risk in HCV-infected cases in comparison to non-infected controls in both retrospective (OR(adjusted)=1.68, 95% CI 1.15-2.20) and prospective studies (HR(adjusted)=1.67, 95% CI 1.28-2.06). Excess risk was also observed in comparison to HBV-infected controls (OR(adjusted)=1.80, 95% CI 1.20-1.40) with suggestive excess observed in HCV+/HIV+ cases in comparison to HIV+ controls (OR(unadjusted)=1.82, 95% CI 1.27-2.38). CONCLUSIONS: Our finding of excess DM risk with HCV infection in comparison to non-infected controls is strengthened by consistency of results from both prospective and retrospective studies. The excess risk observed in comparison to HBV-infected controls suggests a potential direct viral role in promoting DM risk, but this needs to be further examined.
BACKGROUND/AIMS: Several studies found hepatitis C (HCV) increases risk of Type II diabetes mellitus (DM). However, others found no or only sub-group specific excess risk. We performed meta-analyses to examine whether HCV infection does increase DM risk in comparison to the general population and in other sub-groups with increased liver disease rates including with hepatitis B (HBV). METHODS: We followed standard guidelines for performance of meta-analyses. Two independent investigators identified eligible studies through structured keyword searches in relevant databases including PubMed. RESULTS: We identified 34 eligible studies. Pooled estimators indicated significant DM risk in HCV-infected cases in comparison to non-infected controls in both retrospective (OR(adjusted)=1.68, 95% CI 1.15-2.20) and prospective studies (HR(adjusted)=1.67, 95% CI 1.28-2.06). Excess risk was also observed in comparison to HBV-infected controls (OR(adjusted)=1.80, 95% CI 1.20-1.40) with suggestive excess observed in HCV+/HIV+ cases in comparison to HIV+ controls (OR(unadjusted)=1.82, 95% CI 1.27-2.38). CONCLUSIONS: Our finding of excess DM risk with HCV infection in comparison to non-infected controls is strengthened by consistency of results from both prospective and retrospective studies. The excess risk observed in comparison to HBV-infected controls suggests a potential direct viral role in promoting DM risk, but this needs to be further examined.
Authors: S Caronia; K Taylor; L Pagliaro; C Carr; U Palazzo; J Petrik; S O'Rahilly; S Shore; B D Tom; G J Alexander Journal: Hepatology Date: 1999-10 Impact factor: 17.425
Authors: Manuel Romero-Gómez; Maria Del Mar Viloria; Raúl J Andrade; Javier Salmerón; Moisés Diago; Conrado M Fernández-Rodríguez; Raquel Corpas; Marina Cruz; Lourdes Grande; Luis Vázquez; Paloma Muñoz-De-Rueda; Pilar López-Serrano; Ana Gila; María L Gutiérrez; Celia Pérez; Angela Ruiz-Extremera; Emilio Suárez; Jesús Castillo Journal: Gastroenterology Date: 2005-03 Impact factor: 22.682
Authors: A L Mason; J Y Lau; N Hoang; K Qian; G J Alexander; L Xu; L Guo; S Jacob; F G Regenstein; R Zimmerman; J E Everhart; C Wasserfall; N K Maclaren; R P Perrillo Journal: Hepatology Date: 1999-02 Impact factor: 17.425
Authors: Parag Mahale; Eric A Engels; Ruosha Li; Harrys A Torres; Lu-Yu Hwang; Eric L Brown; Jennifer R Kramer Journal: Gut Date: 2017-06-20 Impact factor: 23.059
Authors: Hashem B El-Serag; Israel C Christie; Amy Puenpatom; Diana Castillo; Fasiha Kanwal; Jennifer R Kramer Journal: Aliment Pharmacol Ther Date: 2019-04-01 Impact factor: 8.171
Authors: Stephanie C Melkonian; Melissa A Jim; Brigg Reilley; Jennifer Erdrich; Zahava Berkowitz; Charles L Wiggins; Donald Haverkamp; Mary C White Journal: Cancer Causes Control Date: 2018-07-20 Impact factor: 2.506
Authors: Erikka Loftfield; Neal D Freedman; Gabriel Y Lai; Stephanie J Weinstein; Katherine A McGlynn; Philip R Taylor; Satu Männistö; Demetrius Albanes; Rachael Z Stolzenberg-Solomon Journal: Cancer Prev Res (Phila) Date: 2016-08-29
Authors: Ju Dong Yang; Hager Amed Mohamed; Jessica L Cvinar; Gregory J Gores; Lewis R Roberts; W Ray Kim Journal: Am J Gastroenterol Date: 2016-08-16 Impact factor: 10.864
Authors: Elizabeth M Kiefer; Qiuhu Shi; Donald R Hoover; Robert Kaplan; Russell Tracy; Michael Augenbraun; Chenglong Liu; Marek Nowicki; Phyllis C Tien; Mardge Cohen; Elizabeth T Golub; Kathryn Anastos Journal: J Acquir Immune Defic Syndr Date: 2013-03-01 Impact factor: 3.731